A new therapeutic strategy to improve treatment of aggressive endometrial cancer

by IRB Lleida. Institut de Recerca Biomèdica

Inhibition of the ERK5 protein kinase reduces the proliferation and survival of endometrial cancer cells, and potentiates standard chemotherapy

Read more

ORYZON reports results and corporate update for quarter ended September 30, 2022

by Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third...

Read more

Study Sets the Basis for Identifying Biomarkers of Latent Malaria Vivax Infections

by ISGlobal - Instituto de Salud Global de Barcelona

Using a mouse model, the research team characterized the protein profile of small vesicles secreted by liver cells, where the latent form of the parasite hides

Read more

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

by Ysios Capital

Galecto, Inc., a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline d...

Read more

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

by Ysios Capital

Kala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported...

Read more

ORYZON announces FDA clearance of IND to initiate a collaborative Phase II basket study with iadademstat in R/R patients with Neuroendocrine carcinomas (NECs)

by Oryzon Genomics

Oryzon Genomics S. A., announced today that the FDA has approved the Investigational New Drug (IND) application to initiate a Phase II collaborative study with iadademstat in patients with relapsed/re...

Read more

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage

by Ysios Capital

The trial will evaluate the efficacy and safety of belzupacap sarotalocan (bel-sar) with suprachoroidal administration, for the first-line treatment of early-stage choroidal melanoma (CM).

Read more

BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1

by 3P Biopharmaceuticals

3P Bio will focus on the transfer of the production process as well as the cGMP manufacturing of the drug substance to be used in Phase I and II clinical trials. The novel drug could cure neurodegene...

Read more

La polipíldora recibe el Premio ABC Salud 2022 al mejor medicamento

by Centro Nacional de Investigaciones Cardiovasculares - CNIC

La polipíldora merecedora del premio ABC Salud ha presentado resultados de un estudio que aporta evidencia de una reducción del 33 por ciento en mortalidad por causa cardiovascular.

Read more

Un nuevo fármaco en investigación contra el Alzheimer confirma sus resultados positivos durante la CTAD

by Fundación Pasqual Maragall

Lecanemab reduce los marcadores de amiloide y ha conseguido ralentizar en un 27% el deterioro cognitivo en pacientes en fases iniciales del Alzheimer. Se trata pues del primer fármaco que conseguirí...

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream